Drugs / AZD8601
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02935712 | Dec 2016 → Aug 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03370887 | Feb 2018 → Jun 2021 | systolic heart failure | AstraZeneca | Completed | Met primary |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2021-11-15 | AstraZeneca | Results AZD8601 EPICCURE Phase II trial demonstrated safety and tolerability in patients with heart failure astrazeneca.com ↗
Positive Phase IIa results from the EPICCURE trial demonstrated that AZD8601 met the primary endpoint of safety and tolerability in patients with heart failure. |
| 2021-11-15 | ModernaTX, Inc. | Results Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery q4web.com ↗
The Phase 2 study met the primary endpoint of safety and tolerability of AZD8601. |
| 2019-02-20 | ModernaTX, Inc. | Results Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic q4web.com ↗
The trial met its primary objectives of describing safety and tolerability and secondary objectives of protein production and changes in local blood flow post injection. |
| 2016-07-26 | AstraZeneca | Regulatory AstraZeneca files first clinical trial application in Moderna messenger RNA collaboration astrazeneca.com ↗
26 July 2016 AstraZeneca today announced that it has filed a Clinical Trial Application (CTA) with the Paul Ehrlich Institute and the German Federal Ministry of Health to initiate a Phase I clinical trial of AZD8601. |
| 2016-07-26 | ModernaTX, Inc. | Regulatory Moderna Therapeutics Provides Mid-Year Corporate Update, Announces Continued Clinical Development Progress and Pipeline Acceleration modernatx.com ↗
Today, Moderna and AstraZeneca announced the filing of a Clinical Trial Application (CTA) in Europe for a Phase 1 study of AZD8601, an investigational mRNA-based therapy that encodes for vascular endothelial growth factor-A (VEGF-A). |
| 2016-07-26 | ModernaTX, Inc. | Regulatory AstraZeneca and Moderna Announce Filing of First Clinical Trial Application in Messenger RNA Therapeutics™ Collaboration modernatx.com ↗
AstraZeneca and Moderna Therapeutics today announced that AstraZeneca has filed a Clinical Trial Application (CTA) with the Paul Ehrlich Institute and the German Federal Ministry of Health to initiate a Phase 1 clinical trial of AZD8601. |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02935712 ↗ |
| Modality | Messenger RNA (mRNA) | “AZD8601 (modified VEGF-A RNA)” NCT02935712 ↗ |
| Route | Other | “intradermal (ID) injection” NCT02935712 ↗ |
| Target | VEGFA | “AZD8601 is VEGF-A165 mRNA formulated in biocompatible citrate-buffered saline and optimized for high-efficiency VEGF-A expression” PMID 32728595 ↗ Jun 2020 |